While the role of SMN2 remains elusive, it serves as a promising target for SMA therapy by compounds that elevate the levels of SMN by enhancing SMN2 transcription and/or by correcting SMN2 exon 7 splicing [20–22,26,27]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.